You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The company raised about $73.8 million in net proceeds, which will go toward expansion of its facilities and further development of its sequencing technology.
The company anticipates netting $64.1 million in proceeds from the offering.
The firm sold 15,686,000 shares of common stock at a price of $2.20 per share.
The firm is selling nearly 1.2 million shares at $1.99 per share in a direct offering.
Opko said it may use some of the proceeds to make additional acquisitions.
Vermillion anticipates net proceeds of $20.2 million from the offering of 4 million common shares.
The company has lowered its price target to up to $29.9 million from as much as $33.9 million.
The company said the offering is expected to close mid-February.
The firm said that the overallotment option of 2.1 million shares was exercised, resulting in net proceeds of around $90.5 million from the offering.
The firm will use the funds to support ongoing testing and development of its trisomy 21 non-invasive, pre-natal test.
A German shepherd called Nala has had her genome sequenced.
A coronavirus serology test garners Emergency Use Authorization from the US Food and Drug Administration, but the Los Angeles Times asks: how will tests like that be used?
Certain gene variants in conjunction with a healthy lifestyle may keep brains young, according to New Scientist.
In Science this week: increased CD8 T cell density and increased IFN-gamma response may indicate metastatic prostate cancer patients who will respond to immune checkpoint blockade therapy.